Fennec Pharmaceuticals (FENC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$59.2M

Revenue (quarter)

$17.9M

Revenue growth (year over year)

+85.18%

Gross profit (trailing twelve months)

$55.5M

Gross margin

93.73%

Net income (trailing twelve months)

−$3.3M

Net income (quarter)

$2.0M

Net income growth (year over year)

+162.60%

Net margin

−5.49%

Return on equity

−18.58%

EPS (trailing twelve months)

−$0.12

Book value per share

$1.21

P/E (trailing twelve months)

—

Price to book

8.55

Debt to assets

43.97%

Payout ratio

—

Dividend yield

—

Company profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

• Is Fennec Pharmaceuticals (FENC) profitable?

  No. Fennec Pharmaceuticals reported a net loss of $3.3M over the trailing twelve months.

• How much revenue does Fennec Pharmaceuticals (FENC) make?

  Fennec Pharmaceuticals generated $59.2M in revenue over the trailing twelve months, up 85.18% year over year.

• How do I buy stock in Fennec Pharmaceuticals (FENC)?

  FENC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.